Mirum’s Brelovitug Meets Viral-Reduction Goal in Phase 3 Trial
The AZURE-4 study met its goal of reducing hepatitis delta virus levels as Mirum prepares for a potential FDA marketing application.
Makkler Newsroom · Nov 10, 06:56 PM · 1 min read
Market closed· · USD · Data may be delayed
Avg. target $155.71 (+65.7%)
Prices may be delayed and are for informational purposes only - not investment advice.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.